Several important considerations apply: Individuals with active or severe gastrointestinal disease may experience worsening symptoms due to the gastrointestinal side effects of GLP-1 medications The slowed gastric emptying caused by these drugs could theoretically exacerbate symptoms in people with strictures or obstructive complications of Crohn's disease Weight loss associated with GLP-1 therapy may be inappropriate in patients with Crohn's disease who are already experiencing malnutrition or unintentional weight loss The interaction between GLP-1 medications and the inflammatory processes in IBD is not fully understood Clinical decision-making should involve a thorough assessment of disease activity, nutritional status, presence of complications (such as strictures or fistulas), and the primary indication for GLP-1 therapy
Bumper Offer - Urjas oil 1 X HealthAid L-Glutathione Tablet , , HealthAid L-Glutathione Tablet - HealthAid L-Glutathione Tablet , HealthAid L-Glutathione Tablet - HealthAid L-Glutathione Tablet , , , HealthAid L-Glutathione Tablet HealthAid L-Glutathione Tablet , HealthAid L-Glutathione Tablet - HealthAid L-Glutathione Tablet
One modest difference in views: Those who have heard a lot about these drugs are somewhat more optimistic than those who have heard a little to say they will reduce obesity in the U.S
Drugs (2017) 77:521
View Show Notes From This Episode: Which diet really gives you the best shot at optimal health
